Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates

What happened

Moderna reported third-quarter 2026 revenue of $1.3 billion, GAAP net income of $0.2 billion and diluted earnings per share of $0.38. It raised its 2026 revenue growth outlook to 15%–25%, improved its operating expense outlook by about $0.2 billion, and expects year-end cash of $8.1–$8.3 billion.

Confirmed

Global impact / market context

Higher expected revenue growth could support sales expectations, while the lower operating expense outlook may reduce costs and improve the path toward profitability. The larger projected cash balance gives Moderna more funding to advance products and research without relying as heavily on new financing.

Analyst inference

The update combines reported results with revised full-year expectations, so investors may weigh near-term revenue and earnings against execution over the rest of 2026. Product approvals and trial results may broaden future sales opportunities, but the supplied article provides no sales estimates for them.

Analyst inference

What to watch

1. Track whether subsequent quarterly reports show revenue growth consistent with the raised 15%–25% full-year outlook, since weaker sales could make that target harder to achieve. Analyst inference
2. Watch whether operating expenses follow the improved outlook and whether year-end cash lands within $8.1–$8.3 billion; either result would affect funding available for research. Analyst inference
3. The company reported U.S. FDA approval of mFLUSIVA and positive Phase 3 results for intismeran in melanoma; these are confirmed updates, not proof of future sales. Confirmed

Evidence

• accessnewswire.com